Glaukos Co. (NYSE:GKOS) Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. reduced its stake in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 24.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 56,984 shares of the medical instruments supplier's stock after selling 18,814 shares during the quarter. Assenagon Asset Management S.A. owned about 0.10% of Glaukos worth $8,544,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Harbor Capital Advisors Inc. bought a new position in Glaukos during the 4th quarter valued at about $3,679,000. GAMMA Investing LLC grew its stake in shares of Glaukos by 28.3% during the fourth quarter. GAMMA Investing LLC now owns 2,213 shares of the medical instruments supplier's stock valued at $332,000 after buying an additional 488 shares during the last quarter. Exome Asset Management LLC purchased a new stake in shares of Glaukos in the third quarter worth approximately $3,369,000. Franklin Resources Inc. boosted its holdings in Glaukos by 80.1% during the 3rd quarter. Franklin Resources Inc. now owns 15,621 shares of the medical instruments supplier's stock valued at $2,031,000 after acquiring an additional 6,948 shares during the period. Finally, Tidal Investments LLC lifted its position in shares of Glaukos by 83.1% during the third quarter. Tidal Investments LLC now owns 14,908 shares of the medical instruments supplier's stock worth $1,942,000 after purchasing an additional 6,767 shares during the last quarter. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on GKOS shares. UBS Group began coverage on shares of Glaukos in a research report on Friday, December 6th. They set a "buy" rating and a $182.00 target price on the stock. Morgan Stanley lowered Glaukos from an "equal weight" rating to an "underweight" rating and set a $120.00 target price on the stock. in a research note on Monday, December 2nd. JPMorgan Chase & Co. raised their price objective on Glaukos from $130.00 to $145.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 5th. StockNews.com upgraded shares of Glaukos from a "sell" rating to a "hold" rating in a research note on Monday, October 21st. Finally, Stephens upgraded shares of Glaukos to a "strong-buy" rating in a research note on Monday, December 2nd. One research analyst has rated the stock with a sell rating, two have given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $147.75.

Insider Buying and Selling

In related news, Director Gilbert H. Kliman sold 10,000 shares of the company's stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $150.28, for a total transaction of $1,502,800.00. Following the completion of the transaction, the director now owns 32,336 shares in the company, valued at $4,859,454.08. This represents a 23.62 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Joseph E. Gilliam sold 3,328 shares of Glaukos stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $149.85, for a total value of $498,700.80. Following the completion of the sale, the chief operating officer now owns 102,169 shares in the company, valued at approximately $15,310,024.65. The trade was a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 17,603 shares of company stock valued at $2,605,678. 6.40% of the stock is owned by company insiders.

Glaukos Stock Performance

Shares of GKOS traded up $0.09 during mid-day trading on Monday, reaching $156.60. The company had a trading volume of 529,055 shares, compared to its average volume of 558,098. The stock has a 50 day moving average of $145.94 and a two-hundred day moving average of $133.60. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $8.63 billion, a P/E ratio of -51.85 and a beta of 1.04. Glaukos Co. has a 52-week low of $83.90 and a 52-week high of $161.13.

Glaukos (NYSE:GKOS - Get Free Report) last posted its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.20. The firm had revenue of $96.70 million during the quarter, compared to analyst estimates of $91.50 million. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The business's quarterly revenue was up 23.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.50) EPS. On average, analysts expect that Glaukos Co. will post -1.89 earnings per share for the current year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.